BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32528403)

  • 41. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
    Sun Y; Zhu YM
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: A randomized controlled study.
    Maged AM; Ragab MA; Shohayeb A; Saber W; Ekladious S; Hussein EA; El-Mazny A; Hany A
    Int J Gynaecol Obstet; 2021 Mar; 152(3):395-400. PubMed ID: 33011968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
    Cicek MN; Kahyaoglu I; Kahyaoglu S
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.
    Zhang Y; Liu L; Qin J; Huang H; Xue L; Wang S; Tan W
    Reprod Biol Endocrinol; 2021 Oct; 19(1):158. PubMed ID: 34641897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GnRH antagonist rescue of a short-protocol IVF/ICSI cycle and GnRH agonist triggering to prevent ovarian hyperstimulation syndrome: two case reports.
    Bakas P; Boutas I; Giner M; Panagopoulos P; Aravantinos L
    Clin Exp Obstet Gynecol; 2017; 44(2):279-282. PubMed ID: 29746040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality.
    Orvieto R; Nahum R; Rabinson J; Gemer O; Anteby EY; Meltcer S
    Fertil Steril; 2009 Apr; 91(4 Suppl):1398-400. PubMed ID: 18675974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.
    Pabuccu R; Onalan G; Kaya C
    Fertil Steril; 2007 Oct; 88(4):832-9. PubMed ID: 17428479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.
    Cakmak H; Tran ND; Zamah AM; Cedars MI; Rosen MP
    Fertil Steril; 2014 May; 101(5):1308-14. PubMed ID: 24636401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.